Reported Saturday, Purple Biotech Revealed Results From A Phase 2 Study At ASCO 2024, Showing CM24 Improved Overall Survival And Other Efficacy Endpoints In Pancreatic Cancer
Reported Saturday, Purple Biotech Revealed Results From A Phase 2 Study At ASCO 2024, Showing CM24 Improved Overall Survival And Other Efficacy Endpoints In Pancreatic Cancer
上週六報導，purple biotech在ASCO 2024展示了2期研究結果，顯示CM24可以改善胰臟癌的整體存活率和其他療效指標。
- 26% reduction in risk of death (HR=0.74) and 28% risk reduction in progression or death (HR=0.72) in previously-treated patients administered with CM24+nivolumab+Nal/IRI/5FU/LV vs. standard-of-care(SoC) based on preliminary interim data
- Prolongation of 2.1 months in median overall survival (OS) and 1.9 months in median progression-free survival (PFS) in the CM24+nivolumab+Nal-IRI/5FU/LV regimen vs. standard-of-care
- Data supported by higher objective response rate (ORR) (25% vs 7%), disease control rate (DCR) (63% vs 40%), and decrease in CA19-9 level (61% decrease vs. 34% increase)
- 根據初步的中期數據，先前接受過治療的患者使用CM24 + nivolumab + Nal / IRI / 5FU / LV相比標準慣例治療，死亡風險降低了26％（HR = 0.74），疾病進展或死亡的風險降低了28％（HR = 0.72）。
- 使用 CM24 + nivolumab + Nal-IRI / 5FU / LV 方案相比標準慣例治療，中位總生存期（OS）延長了2.1個月，中位無進展生存期（PFS）延長了1.9個月。
- 數據支持使用 CM24 + nivolumab + Nal / IRI / 5FU / LV 方案較之標準慣例治療可獲得更高的客觀緩解率（ORR）（25％ vs 7％），疾病控制率（DCR）（63％ vs 40％）以及血清CA19-9水平下降（61％下降 vs 34％上升）。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。